Skip to content
OpenCapital
Get started

Oric Pharmaceuticals, Inc. ORIC EPS (Diluted)

EPS (Diluted) at other companies

Pfizer logo
PfizerPFE
$0.47-9.6%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$0.96+49.5%
CG Oncology logo
CG OncologyCGON
-$0.71-57.8%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
-$0.52-44.4%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$2.15+23.2%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$0.79-142%

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.0%
Enterprise value$923.07M+23.5%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0×0.0×
Current ratio16.3×+4.3×

Where this comes from

Reported directly by Oric Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s EPS (diluted)?
Oric Pharmaceuticals, Inc. (ORIC) reported EPS (diluted) of -$0.34 in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s EPS (diluted) changed year-over-year?
Oric Pharmaceuticals, Inc.'s EPS (diluted) increased by 19.0% year-over-year, from -$0.42 to -$0.34.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s EPS (diluted)?
Over 4 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s EPS (diluted) has grown at a -7.9% compound annual growth rate (CAGR), from -$2.07 to -$1.49.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.